ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2307건의 자료가 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2300 | Completed | A Clinical Study Evaluating Inhaled Aviptadil on COVID-19 | Covid19 | Drug: Inhaled Aviptadil Drug: Placebo |
Phase 2 | Centurion Pharma | INDUSTRY | 80 | All | 18 Years ~ 70 Years | Ba?kent University School of Medicine, Ankara, Turkey Hacettepe University School of Medicine, Ankara, Turkey Dicle Universitesi Tıp Fakultesi Hastanesi, Diyarbakır, Turkey Ba?ak?ehir Cam ve Sakura ?ehir Hastanesi, Istanbul, Turkey Health Sciences University Yedikule Training and Research Hospital, Istanbul, Turkey Prof. Dr. Feriha Oz Acil Durum Hastanesi, Istanbul, Turkey Prof. Dr. Murat Dilmener Acil Durum Hastanesi, Istanbul, Turkey Kocaeli Universitesi Tıp Fakultesi Hastanesi, Kocaeli, Turkey Karadeniz Teknik Universitesi Tıp Fakultesi Hastanesi, Trabzon, Turkey |
| 2299 | Recruiting | A Clinical Study on Safety and Effectiveness of Mesenchymal Stem Cell Exosomes for the Treatment of COVID-19. | COVID-19 Pneumonia | Biological: Extracellular Vesicles from Mesenchymal Stem Cells | Early Phase 1 | First Affiliated Hospital of Wenzhou Medical University, REGEN-αGEEK (SHENZHEN) MEDICAL TECHNOLOGY CO., LTD. | OTHER | 240 | All | 18 Years ~ 75 Years | The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China |
| 2298 | Completed | A Clinical Study to Assess Preliminary Efficacy, Safety and Tolerability of HH-120 Nasal Spray in COVID-19 Patients | Coronavirus Disease 2019(COVID-19) | Biological: HH-120 Nasal Spray | Not Applicable | Beijing Ditan Hospital | OTHER | 111 | All | 18 Years ~ 65 Years | Beijing Ditan Hospital, Capital Medical University, Beijing, Beijing, China |
| 2297 | Completed | A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus | Covid-19 Disease | Drug: Enisamium Iodide Drug: Placebo |
Phase 3 | Joint Stock Company "Farmak" | INDUSTRY | 592 | All | 18 Years ~ 99 Years | Municipal Enterprise "Volyn Regional Clinical Hospital" of Volyn Regional Council, Dept. Pulmonology, Lutsk, Volynsk, Ukraine Municipal Non-Commercial Enterprise 'City Clinical Hospital #3' Chernivtsi City Council, Dept. Therapeutics #1, Dept. Therapeutics #2, Higher State Educational Institution of Ukraine 'Bukovinian State University', Chernivtsi, Ukraine Municipal Non-Commercial Enterprise 'Regional Clinical Infection Hospital Ivano-Frankivsk Regional Council', Dept. #2, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine Municipal Non-Commercial Enterprise 'Regional Clinical Hospital Ivano-Frankivsk Regional Council', Dept. Allergology, Ivano-Frankivsk, Ukraine Municipal Non-Commercial Enterprise 'City Clinical Hospital #1 Ivano-Frankivsk City Council', Dept. Therapeutics, Ivano-Frankivsk, Ukraine Municipal Non-Commercial Enterprise Kharkiv Regional Council 'Regional Clinical Infection Hospital', 1st Department, Kharkiv National Medical University, Chair of Infectious Diseases, Kharkiv, Ukraine Municipal Non-Commercial Enterprise 'Olexandrivska Clinical Hospital of Kyiv' Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine Municipal Non-Commercial Enterprise "Kyiv City Clinical Hospital #9" Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine Municipal Non-Commercial Enterprise Lviv Regional Council 'Lviv Regional Infection Hospital', Fourth Diagnostic Department, Lviv, Ukraine Ukraine Medical Stomatological Academy, Chair of Infectious Diseases with Epidemiology, Municipal Non-Commercial Enterprise 'Poltava Regional Infection Hospital Poltava Regional Council', Dept. Respiratory Infections, Poltava, Ukraine Municipal Non-Commercial Enterprise 'Central Clinical Hospital' of Rivne City Council, Hepatic Centre - Infections, Rivne, Ukraine Municipal Non-Commercial Enterprise 'Regional Clinical Infectional Hospital' Transcarpathian Regional Council, Dept. Infections (Adult), Uzhhorod, Ukraine Municipal Non-Сommercial Enterprise 'Vinnytsya City Clinical Hospital #1', Infectious Department, National Pirogov Memorial Medical University, Dept. Infections, Vinnytsya, Ukraine |
| 2296 | Completed | A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19 | COVID-19 | Drug: SIM0417 Drug: Placebo |
Phase 3 | Jiangsu Simcere Pharmaceutical Co., Ltd. | INDUSTRY | 1208 | All | 18 Years | Hefei First People's Hospital, Hefei, Anhui, China Beijing Ditan Hospital Captial Medical University, Beijing, Beijing, China Chongqing Public Health Medical Center, Chongqing, Chongqing, China The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China Guangzhou Eighth People's Hospital Guangzhou Medical University, Guangzhou, Guangdong, China Maoming People's Hospital, Maoming, Guangdong, China Qingyuan People's Hospital, Qingyuan, Guangdong, China The Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China Central People's Hospital of Zhanjiang, Zhanjiang, Guangdong, China The Fifth Affiliated Hospital Sun Yat-Sen University, Zhuhai, Guangdong, China GuiZhou Province People's Hospital, Guiyang, Guizhou, China Haikou people's Hospital, Haikou, Hainan, China Hainan Third People's Hospital, Sanya, Hainan, China Mudanjiang Kangan Hospital, Mudanjiang, Heilongjiang, China Wuhan Jinyintan Hospital, Wuhan, Hubei, China The First Hospital of Changsha, Changsha, Hunan, China The Second Hospital of Nanjing, Nanjing, Jiangsu, China ZhongDa Hospital SouthEast University, Nanjing, Jiangsu, China The Fifth People's Hospital of Suzhou, Suzhou, Jiangsu, China Taizhou People's Hospital, Taizhou, Jiangsu, China Wuxi No.5 People's Hospital, Wuxi, Jiangsu, China Xuzhou Infectious Disease Hospital, Xuzhou, Jiangsu, China Subei People's Hospital of Jiangsu province, Yangzhou, Jiangsu, China The Third People's Hospital of Zhenjiang, Zhenjiang, Jiangsu, China The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China The Sixth People's Hospital of ShenYang, Shenyang, Liaoning, China Shandong Public Health Clinical Center, Jinan, Shandong, China Shanghai Public Health Clinical Center, Shanghai, Shanghai, China Public health clinical center of Chengdu, Chengdu, Sichuan, China Suining Central Hospital, Suining, Sichuan, China Tianjin first center hospital, Tianjin, Tianjin, China Affliated Hangzhou XiXi Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China Huzhou Central Hospital, Huzhou, Zhejiang, China HwaMei Hospital University of Chinese Academy of Sciences, Ningbo, Zhejiang, China Wenzhou Central Hospital, Wenzhou, Zhejiang, China |
| 2295 | Completed | A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster | SARS-CoV-2 Infection | Biological: Recombinant COVID-19 Vaccine (Sf9 Cell) Biological: COVID-19 Vaccine (Vero Cell), Inactivated |
Not Applicable | WestVac Biopharma Co., Ltd., West China Hospital | INDUSTRY | 120 | All | 18 Years ~ 60 Years | West China Hospital of Sichuan University, Chengdu, Sichuan, China |
| 2294 | Unknown status | A Clinical Trial for Azvudine in the Treatment of Novel Coronavirus Pneumonia (COVID-19） | COVID-19 | Drug: FNC+Standard of Care Drug: FNC dummy tablet+Standard of Care |
Not Applicable | HeNan Sincere Biotech Co., Ltd | INDUSTRY | 342 | All | 18 Years ~ 99 Years |
